A Protocolized Intravenous Epoprostenol Pathway for Frostbite: A Canadian Burn Center Quality Improvement and Implementation Report
Journal of Burn Care & Research · 2026
DOI: 10.1093/jbcr/irag117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Burn Care & Research, 2026. Verfasst von Rimona Natanson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. Hauptthemen laut MEDLINE: Epoprostenol, Frostbite, Quality Improvement. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Severe frostbite is a dynamic microvascular injury that can progress to delayed tissue loss despite appropriate initial care. Contemporary management emphasizes rapid rewarming, antithromboxane therapy, clinical grading, selective thrombolysis, and prostacyclin-based treatment. Iloprost is the prostacyclin analogue most often described, but access may be delayed in some Canadian settings. We developed and implemented a monitored intravenous epoprostenol pathway for Cauchy grade 2-4 frostbite and retrospectively evaluated 23 patients treated between December 2017 and November 2025. The pathway incorporated rapid rewarming, grading, topical and systemic antithromboxane therapy, eligibility criteria, dose titration, physiologic monitoring, dose modification, multidisciplinary care, and follow-up. Overall, 153 of 216 affected digits were preserved. Preservation varied by severity: 62 of 65 grade 2 digits, 74 of 100 grade 3 digits, and 7 of 41 grade 4 digits were preserved. Twelve patients avoided amputation altogether. Mean treatment duration was 3.8 days, and most patients reached 8 ng/kg/min at least once. Documented adverse effects or dose-limiting symptoms occurred in 9 patients and were managed with dose reduction or temporary interruption. Available records did not identify thrombolytic therapy, permanent discontinuation for adverse reaction or grade 2 reassessment, or serious drug-attributed adverse events. Protocol-guided intravenous epoprostenol was feasible and generally well tolerated. Findings should be interpreted as descriptive and hypothesis-generating rather than evidence of treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
- Department of Pharmacy, Sunnybrook Health Sciences Centre, 0275 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
- Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, 149 College Street, Toronto, Ontario M5T 1P5, Canada.
- Interdepartmental Division of Critical Care, University of Toronto, 585 University Ave, Toronto, Ontario M5G 2N2, Canada.
- Department of Medicine, Division of Respirology, University Health Network, Toronto, 190 Elizabeth Street, Ontario M5G 2C4, Canada.
ORCID-Profile: David Wallace, Alan D Rogers
Zitieren
APA
Natanson, R., Adibfar, A., Au, A., Tillman, B., Lalji, S., Callahan, A., Wallace, D., Mason, S., & Rogers, A. D. (2026). A Protocolized Intravenous Epoprostenol Pathway for Frostbite: A Canadian Burn Center Quality Improvement and Implementation Report. Journal of Burn Care & Research. https://doi.org/10.1093/jbcr/irag117
Vancouver
Natanson R, Adibfar A, Au A, Tillman B, Lalji S, Callahan A, et al. A Protocolized Intravenous Epoprostenol Pathway for Frostbite: A Canadian Burn Center Quality Improvement and Implementation Report. Journal of Burn Care & Research. 2026. doi:10.1093/jbcr/irag117
BibTeX
@article{Natanson2026,
author = {Natanson, Rimona and Adibfar, Alex and Au, Anita and Tillman, Bourke and Lalji, Shabana and Callahan, Ashley and Wallace, David and Mason, Stephanie and Rogers, Alan D},
title = {A Protocolized Intravenous Epoprostenol Pathway for Frostbite: A Canadian Burn Center Quality Improvement and Implementation Report},
journal = {Journal of Burn Care & Research},
year = {2026},
doi = {10.1093/jbcr/irag117}
}
EUVIMED